Advertisement

Current Treatment Options in Neurology

, Volume 5, Issue 1, pp 55–68 | Cite as

Current complementary and alternative therapies for multiple sclerosis

  • Allen C. Bowling
  • Thomas M. Stewart
Article

Opinion statement

The use of complementary and alternative medicine (CAM) appears to be high in the general population and in patients with multiple sclerosis (MS). There are no diets or dietary supplements that are definitely effective in altering the disease course in MS. However, diets and dietary supplements that increase the intake of polyunsaturated fatty acids may produce mildly beneficial effects. Because these approaches are not definitely effective, they may be of limited interest to physicians and other conventional health providers. In contrast, for patients with MS, these interventions may be of considerable interest, because they may be mildly effective and are inexpensive and relatively safe. Vitamin D, ginkgo biloba, cannabinoids, and Padma 28 produce immunomodulatory actions and therapeutic effects in experimental autoimmune encephalomyelitis. However, for these compounds, there are not enough clinical trial data or safety information to support their use as disease-modifying therapies. The role of antioxidant compounds in MS is unclear. There is no evidence that vitamin B12 supplementation or gluten-free diets are effective MS therapies. Conventional health providers can play an important role in the care of MS patients by being open to discuss CAM therapies and by providing objective MS-relevant CAM information.

Keywords

Multiple Sclerosis Experimental Autoimmune Encephalomyelitis Multiple Sclerosis Patient CoQ10 Main Drug Interaction 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Bashir K: Current immunotherapy for demyelinating diseases. Arch Neurol 2002, 59:726–731.PubMedCrossRefGoogle Scholar
  2. 2.
    Bever C: Multiple sclerosis: symptomatic treatment. Curr Treat Opt Neurol 1999, 1:221–237.Google Scholar
  3. 3.
    Eisenberg D, Davis R, Ettner S, et al.: Trends in alternative medicine use in the United States, 1990–1997. JAMA 1998, 280:1569–1575. An excellent, frequently referenced study that evaluated trends of CAM use in the general population in the US. The original study by this group in 1990 generated much of the initial interest in CAM in the US.PubMedCrossRefGoogle Scholar
  4. 4.
    Bowling A, Ibrahim R, Stewart T: Alternative medicine and multiple sclerosis: an objective review from an American perspective. Int J MS Care 2000, 2:14–21.Google Scholar
  5. 5.
    Berkman C, Pignotti M, Cavallo P, et al.: Use of alternative treatments by people with multiple sclerosis. Neurorehab Neural Repair 1999, 13:243–254.CrossRefGoogle Scholar
  6. 6.
    Schwartz C, Laitin E, Brotman S, et al.: Utilization of unconventional treatments by persons with MS: is it alternative or complementary? Neurology 1999, 52:626–629.PubMedGoogle Scholar
  7. 7.
    Bashir K, Buchwald L, Coyle P, et al.: Optimizing immunomodulatory therapy for MS patients. Int J MS Care 2002, 4:3–7.Google Scholar
  8. 8.
    Kaufman M: Combining therapies with interferon beta for relapsing and early progressive MS: a review. Int J MS Care 2002, 4:50–65.Google Scholar
  9. 9.
    Calder P: Dietary fatty acids and lymphocyte functions. Proc Nutr Soc 1998, 57:487–502. This is a nice review of the effects of omega-3 and omega-6 fatty acids on lymphocytes. This article is part of a larger series of articles that were written for a symposium that focused on the effects of lipids on the immune system.PubMedCrossRefGoogle Scholar
  10. 10.
    Harbige L: Dietary n-6 and n-3 fatty acids in immunity and autoimmune disease. Proc Nutr Soc 1998, 57:555–562.PubMedCrossRefGoogle Scholar
  11. 11.
    Bates D: Lipids and multiple sclerosis. Biochem Soc Trans 1988, 17:289–291.Google Scholar
  12. 12.
    Martinez M, Vasquez E: MRI evidence that docosahexaenoic acid ethyl ester improves myelination in generalized peroxisomal disorders. Neurology 1998, 51:26–32.PubMedGoogle Scholar
  13. 13.
    Beblo S, Reinhardt H, Muntau A, et al.: Fish oil supplementation improves visual evoked potentials in children with phenylketonuria. Neurology 2001, 57:1488–1491.PubMedGoogle Scholar
  14. 14.
    Swank R: Multiple sclerosis: twenty years on low fat diet. Arch Neurol 1970, 23:460–474.PubMedGoogle Scholar
  15. 15.
    Swank R, Dugan B: Effect of low saturated fat diet in early and late cases of multiple sclerosis. Lancet 1990, 336:37–39.PubMedCrossRefGoogle Scholar
  16. 16.
    Millar J, Zilkha K, Langman M, et al.: Double-blind trial of linoleate supplementation of the diet in multiple sclerosis. BMJ 1973, 1:765–768.PubMedGoogle Scholar
  17. 17.
    Bates D, Fawcett P, Shaw D, et al.: Polyunsaturated fatty acids in treatment of acute remitting multiple sclerosis. BMJ 1978, 2:1390–1391.PubMedGoogle Scholar
  18. 18.
    Paty D: Double-blind trial of linoleic acid in multiple sclerosis. Arch Neurol 1983, 40:693–694.PubMedGoogle Scholar
  19. 19.
    Dworkin R, Bates D, Millar J, et al.: Linoleic acid and multiple sclerosis: a reanalysis of three double-blind trials. Neurology 1984, 34:1441–1445.PubMedGoogle Scholar
  20. 20.
    Bates D, Fawcett P, Shaw D, et al.: Trial of polyunsaturated fatty acids in non-relapsing multiple sclerosis. BMJ 1977, 10:932–933.Google Scholar
  21. 21.
    Jellin J, Gregory P, Batz F, et al.: Natural Medicines Comprehensive Database: Pharmacist’s Letter/Prescriber’s Letter Natural Medicine Comprehensive Database. Stockton: Therapeutic Research Faculty; 2002. An excellent reference book that provides detailed evidencebased information about many different dietary supplements.Google Scholar
  22. 22.
    Sarubin A: The Health Professional’s Guide to Popular Dietary Supplements. Chicago: American Dietetic Association; 1999.Google Scholar
  23. 23.
    Gibson R, Neumann M: Gamma-linolenic acid (GLA) content of encapsulated evening primrose oil products. Lipids 1992, 27:82–84.PubMedCrossRefGoogle Scholar
  24. 24.
    Zock P, Katan M: Linoleic acid intake and cancer risk: a review and meta-analysis. Am J Clin Nutr 1998, 68:5–7.Google Scholar
  25. 25.
    Harris P, Embree N: Quantitative consideration of the effect of polyunsaturated fatty acid content of the diet upon the requirements for vitamin E. Am J Clin Nutr 1963, 13:385–392.PubMedGoogle Scholar
  26. 26.
    Bates D, Cartlidge N, French J, et al.: A double-blind controlled trial of long chain n-3 polyunsaturated fatty acids in the treatment of multiple sclerosis. J Neurol Neurosurg Psych 1989, 52:18–22.Google Scholar
  27. 27.
    Goldberg P, Fleming M, Picard H: Multiple sclerosis: decreased relapse rate through dietary supplementation with calcium, magnesium and vitamin D. Med Hyp 1986, 21:193–200.CrossRefGoogle Scholar
  28. 28.
    Nordvik I, Myhr K-M, Nyland H, et al.: Effect of dietary advice and n-3 supplementation in newly diagnosed MS patients. Acta Neurol Scand 2000, 102:143–149.PubMedCrossRefGoogle Scholar
  29. 29.
    Weinstock-Guttman B, Baier M, Peterken L, et al.: A randomized study of low-fat diet with w-3 fatty acid supplementation in patients with relapsing-remitting multiple sclerosis (RRMS). Neurology 2002, 58:A461–462.Google Scholar
  30. 30.
    Saynor R, Gillott T: Changes in blood lipids and fibrinogen with a note on safety in a long term study on the effects of n-3 fatty acids in subjects receiving fish oil supplements and followed for seven years. Lipids 1992, 27:533–538.PubMedCrossRefGoogle Scholar
  31. 31.
    Lange L, Shiner M: Small bowel abnormalities in multiple sclerosis. Lancet 1976, 2:1319–1322.PubMedCrossRefGoogle Scholar
  32. 32.
    Jones P, Pallis C, Peters T: Morphological and biochemical findings in jejunal biopsies from patients with multiple sclerosis. J Neurol Neurosurg Psych 1979, 42:402–406.Google Scholar
  33. 33.
    Hunter A, Rees B, Jones L: Gluten antibodies in patients with multiple sclerosis. Human Nutr Appl Nutr 1984, 38:142–143.Google Scholar
  34. 34.
    Hewson D: Is there a role for gluten-free diets in multiple sclerosis? Human Nutr Appl Nutr 1984, 38:417–420.Google Scholar
  35. 35.
    Liversedge L: Treatment and management of MS. Br Med Bull 1977, 33:78–83.PubMedGoogle Scholar
  36. 36.
    Cantorna M, Humpal-Winter J, DeLuca H: In vivo upregulation of interleukin-4 is one mechanism underlying the immunoregulatory effects of 1,25-dihydroxyvitamin D3. Arch Biochem Biophys 2000, 377:135–138.PubMedCrossRefGoogle Scholar
  37. 37.
    Van Etten E, Brainistreanu D, Verstuyf A, et al.: Analogs of I,25-dihydroxyvitamin D3 as dose-reducing agents for classical immunosuppressants. Transplantation 2000, 69:1932–1942.PubMedCrossRefGoogle Scholar
  38. 38.
    Cantorna M, Hayes C, DeLuca H: 1,25-dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proc Natl Acad Sci U S A 1996, 93:7861–7864.PubMedCrossRefGoogle Scholar
  39. 39.
    Fleming J, Hummel A, Beinlich B, et al.: Vitamin D treatment of relapsing-remitting multiple sclerosis (RRMS): a MRI-based pilot study. Neurology 2000, 54:A338.Google Scholar
  40. 40.
    Herndon R, Mohandas N: Osteoporosis in multiple sclerosis: a frequent, serious, and under-recognized problem. Int J MS Care 2000, 2:5.Google Scholar
  41. 41.
    Smeltzer S, Zimmerman V, Capriotti T, et al.: Osteoporosis risk factors and bone mineral density in women with MS. Int J MS Care 2000, 4:17–29.Google Scholar
  42. 42.
    Greco A, Minghetti L, Sette G, et al.: Cerebrospinal fluid isoprostane shows oxidative stress in patients with multiple sclerosis. Neurology 1999, 53:1876–1879.PubMedGoogle Scholar
  43. 43.
    Giovannoni G, Heales S, Land J, et al.: The potential role of nitric oxide in multiple sclerosis. Mult Scler 1998, 4:212–216.PubMedGoogle Scholar
  44. 44.
    Hooper D, Bagasra O, Marini J, et al.: Prevention of experimental allergic encephalomyelitis by targeting nitric oxide and peroxynitrite: implications for the treatment of multiple sclerosis. Proc Natl Acad Sci U S A 1997, 94:2528–2533.PubMedCrossRefGoogle Scholar
  45. 45.
    LeVine S: The role of reactive oxygen species in the pathogenesis of multiple sclerosis. Med Hyp 1992, 39:271–274.CrossRefGoogle Scholar
  46. 46.
    Trapp B, Ransohoff R, Fisher E, et al.: Neurodegeneration in multiple sclerosis: relationship to neurological disability. Neuroscientist 1999, 5:1–7.CrossRefGoogle Scholar
  47. 47.
    Bowling A, Beal M: Bioenergetic and oxidative stress in neurodegenerative diseases. Life Sci 1995, 56:1151–1171.PubMedCrossRefGoogle Scholar
  48. 48.
    Grimble R: Effect of antioxidative vitamins on immune function with clinical applications. Int J Vitam Nutr Res 1997, 67:312–320.PubMedGoogle Scholar
  49. 49.
    Harbige L: Nutrition and immunity with emphasis on infection and autoimmune disease. Nutr Health 1996, 10:285–312.PubMedGoogle Scholar
  50. 50.
    Mai J, Sorenson P, Hansen J: High dose antioxidant supplementation to MS patients: effects on glutathione peroxidase, clinical safety, and absorption of selenium. Biol Trace Elem Res 1990, 24:109–117.PubMedCrossRefGoogle Scholar
  51. 51.
    Marracci G, McKeon G, Jones R, et al.: Alpha-lipoic acid inhibit matrix matalloproteinase-9: implications for effects on T-cell migration and treatment of multiple sclerosis. Neurology 2002, 58:A420.Google Scholar
  52. 52.
    Reynolds E, Bottiglieri T, Laundy M, et al.: Vitamin B12 metabolism in multiple sclerosis. Arch Neurol 1992, 49:649–652.PubMedGoogle Scholar
  53. 53.
    Goodkin D, Jacobsen D, Galvez N, et al.: Serum cobalamin deficiency is uncommon in multiple sclerosis. Arch Neurol 1994, 51:1110–1114.PubMedGoogle Scholar
  54. 54.
    Kira J, Tobimatus S, Goto I: Vitamin B12 metabolism and massive-dose methyl vitamin B12 therapy in Japanese patients with multiple sclerosis. Int Med 1994, 33:82–86.Google Scholar
  55. 55.
    Rowland L: Merritt’s Neurology, edn 10. Philadelphia: Lippincott Williams & Wilkins; 2000.Google Scholar
  56. 56.
    Winslow L, Kroll D: Herbs as medicines. Arch Intern Med 1998, 158:2192–2199.PubMedCrossRefGoogle Scholar
  57. 57.
    Bowling A: Alternative Medicine and Multiple Sclerosis. New York: Demos Medical Publishing; 2001. A book that reviews the safety and efficacy of diets, dietary supplements, and many other CAM therapies in the context of MS.Google Scholar
  58. 58.
    Braquet P, Esanu A, Buisine E, et al.: Recent progress in ginkgolide research. Med Res Rev 1991, 11:295–355.PubMedCrossRefGoogle Scholar
  59. 59.
    Oken B, Storzbach D, Kaye J: The efficacy of ginkgo biloba on cognitive function in Alzheimer disease. Arch Neurol 1998, 55:1409–1415.PubMedCrossRefGoogle Scholar
  60. 60.
    Brochet B, Orgogozo J, Guinot P, et al.: Étude pilote d’un inhibiteur spécifique du PAF-acéther, le ginkgolide B dans le traitement des poussées aiguës de scléroses en plaques. Rev Neurol (Paris) 1992, 48:229–301.Google Scholar
  61. 61.
    Brochet B, Guinot P, Orgogozo J, et al.: Double-blind, placebo controlled, multicentre study of ginkgolide B in treatment of acute exacerbations for multiple sclerosis. The Ginkgolide Study Group in multiple sclerosis. J Neurol Neurosurg Psychiatry 1995, 58:360–362.PubMedCrossRefGoogle Scholar
  62. 62.
    Kenney C, Norman, M, Jacobson M, et al.: A doubleblind, placebo-controlled, modified crossover pilot study of the effects of ginkgo biloba on cognitive and functional abilities in multiple sclerosis. Neurology 2002, 58:A458-A459.Google Scholar
  63. 63.
    Iversen L: The Science of Marijuana. New York: Oxford University Press; 2000. A well-written, referenced book that provides an objective review of a broad range of scientific and clinical studies of marijuana.Google Scholar
  64. 64.
    Parolaro D: Presence and functional regulation of cannabinoid receptors in immune cells. Life Sci 1999, 65:637–644.PubMedCrossRefGoogle Scholar
  65. 65.
    Wirguin I, Mechoulam R, Breuer A, et al.: Suppression of experimental autoimmune encephalomyelitis by cannabinoid. Immunopharmacol 1994, 28:209–214.CrossRefGoogle Scholar
  66. 66.
    Achiron A, Miron S, Lavie V, et al.: Dexanabinol (HU-211) effect on experimental autoimmune encephalomyelitis: implications for the treatment of acute relapses of multiple sclerosis. J Neuroimmunol 2000, 102:26–31.PubMedCrossRefGoogle Scholar
  67. 67.
    Baker D, Pryce G, Croxford J, et al.: Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature 2000, 404:84–87.PubMedCrossRefGoogle Scholar
  68. 68.
    Consroe P, Musty R, Rein J, et al.: The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur Neurol 1997, 38:44–48.PubMedGoogle Scholar
  69. 69.
    Ungerleider J, Andyrsiak T, Fairbanks L, et al.: Delta-9-THC in the treatment of spasticity associated multiple sclerosis. Adv Alc Subst Abuse 1987, 7:39–50.Google Scholar
  70. 70.
    Francis G: Marihuana and Medicine. Totowa: Humana Press Inc; 1999.Google Scholar
  71. 71.
    Killestein J, Hoogervorst E, Reif M, et al.: Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology 2002, 58:1404–1406.PubMedGoogle Scholar
  72. 72.
    Badnaev V, Kozlowski P, Schuller-Levis G, et al.: The therapeutic effect of an herbal formula badmaev 28 (Padma 28) on experimental allergic encephalomyelitis (EAE) in SJL/J mice. Phytother Res 1999, 13:218–221.CrossRefGoogle Scholar
  73. 73.
    Korwin-Piotrowska T, Nocon A, Stankowska-Chomicz A, et al.: Experience of padma 28 in multiple sclerosis. Phytother Res 1992, 6:133–136.CrossRefGoogle Scholar

Copyright information

© Current Science Inc 2003

Authors and Affiliations

  • Allen C. Bowling
    • 1
  • Thomas M. Stewart
    • 1
  1. 1.Complementary and Alternative Medicine ProgramRocky Mountain Multiple Sclerosis CenterEnglewoodUSA

Personalised recommendations